MarketCapExport financials
Sanara MedTech (SMTI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Sanara MedTech Financial Ratios 2025-2009 | SMTI
Brief overview of Sanara MedTech 's valuation multiples
The comparison uses the five latest available annual observations between 2021 and 2025.
Market valuation is represented by P/E 4.15x (median 19.7x), EV/EBITDA 18.34x (median 30.2x), P/S 1.51x (median 4.62x). On average, this basket is 39.3% below its own five-year medians. The market values the business at a discount to recent history.
Earnings yield calculated as 1/P/E is about 24.1%, showing current profit per unit of share price.
The latest available business-quality ratios are ROE 6.3%, ROA 51.5%, ROCE 13.4%. Profitability sends a weak positive signal and leaves the business sensitive to cost or demand pressure.
PEG of 0.76x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.
A shorter cycle, from 234.8 days to 162.6 days, indicates faster release of cash from operations.
What the ratios show
Sanara MedTech 's valuation is lower, but weak quality metrics call for caution. Recovery in earnings and capital returns is the key catalyst.
Annual Financial Ratios Sanara MedTech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.2 | 15.9 | 69.7 | -39.8 | -27.4 | -47.3 | -14.9 | -18.1 | 23.5 | -15.7 | -4.8 | -2.3 | -2.6 | -1.7 | -1.4 | -404.5 | - | |
P/S |
1.5 | 1.8 | 4.6 | 6.9 | 9.0 | 13.2 | 3.6 | 1.9 | 1.2 | 1.2 | 1.9 | 2.0 | 6.3 | 2.7 | 8.2 | 2951.1 | - |
EPS |
-4.4 | -1.1 | -0.5 | -1 | -1.1 | -0.8 | -1.3 | - | - | -0.0 | -0.0 | -0.0 | -0.1 | -0.0 | -0.2 | -0.2 | - |
EV (Enterprise Value) |
206 M | 187 M | 324 M | 327 M | 205 M | 210 M | 40.2 M | 12.6 M | 9.45 M | 8.28 M | 8.88 M | 7.08 M | 14.3 M | 8.3 M | 25.7 M | 2.69 B | 4.36 K |
EBITDA per Share |
1.3 | 0.73 | -0.07 | -1.28 | -0.92 | -0.822 | -1.18 | -0.187 | 0.2 | -0.195 | -0.848 | -2.28 | -3.7 | -8.48 | -2.44 | -0.06 | - |
EV/EBITDA |
18.3 | 30.2 | -600.3 | -32.2 | -29.6 | -43.7 | -14.7 | -28.7 | 32.8 | -32.6 | -8.2 | -2.4 | -3.8 | -0.6 | -14.1 | -1343.8 | - |
PEG |
-0.02 | -0.07 | 0.76 | -0.56 | -1.18 | 0.86 | 0.05 | 0.06 | 0.2 | -0.31 | -0.14 | -0.06 | 0.04 | -0.02 | 0.02 | - | - |
P/B |
26.3 | 3.9 | 6.7 | 7.6 | 7.2 | 33.5 | 6.4 | 9.8 | 76.0 | -15.4 | -5.0 | -6.4 | -4.4 | -0.8 | -4.7 | 4816.6 | - |
P/CF |
23.0 | -6449.5 | -92.5 | -56.9 | -45.1 | -36.3 | -10.9 | 40.4 | -34.5 | 16.0 | -5.3 | -3.1 | -5.9 | -2.6 | -52.5 | -1799.7 | - |
ROE % |
632.53 | 24.53 | 9.60 | -18.98 | -25.85 | -70.83 | -42.55 | -54.01 | 323.11 | 98.27 | 105.44 | 276.01 | 168.04 | 48.49 | 330.07 | -1190.70 | - |
ROA % |
51.50 | 10.97 | 5.83 | -13.00 | -21.77 | -44.33 | -25.31 | -19.74 | 14.94 | -19.15 | -96.31 | -152.05 | -424.51 | -132.41 | -332.44 | -97.91 | - |
ROCE % |
13.45 | 1.72 | -6.98 | -25.90 | -23.90 | -79.61 | -31.02 | -18.55 | 139.12 | -35.03 | 1433.94 | 252.52 | 118.63 | 149.08 | 59.22 | -249.29 | - |
Current Ratio |
1.1 | 1.8 | 2.5 | 3.2 | 5.8 | 1.3 | 3.4 | 2.4 | 1.0 | 1.4 | 0.8 | 0.5 | 0.2 | 0.2 | 0.2 | 1.1 | - |
DSO |
- | - | 19.1 | 38.5 | 38.4 | 53.1 | 41.4 | 13.4 | 48.4 | 52.6 | 49.0 | 38.6 | 46.8 | 63.4 | 189.2 | 90.2 | - |
DIO |
162.6 | 167.5 | 192.1 | 160.6 | 252.4 | 259.3 | 225.3 | - | 322.1 | 134.8 | 167.7 | 182.8 | 141.6 | 207.6 | 123.8 | - | - |
DPO |
- | - | 32.4 | 52.5 | 56.0 | 111.7 | 122.6 | 84.5 | 129.3 | 92.2 | 91.0 | 95.5 | 88.5 | 93.8 | 2.2 | - | - |
Operating Cycle |
162.6 | 167.5 | 211.2 | 199.1 | 290.8 | 312.3 | 266.7 | 13.4 | 370.6 | 187.4 | 216.7 | 221.4 | 188.4 | 271.1 | 313.0 | 90.2 | - |
Cash Conversion Cycle |
162.6 | 167.5 | 178.9 | 146.5 | 234.8 | 200.6 | 144.2 | -71.1 | 241.3 | 95.3 | 125.7 | 125.9 | 99.9 | 177.3 | 310.8 | 90.2 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Sanara MedTech
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.06 | 0.05 | - | -3.52 | -0.23 | -0.41 | - | -0.34 | -0.41 | -0.21 | - | -0.13 | -0.22 | -0.14 | - | -0.18 | 0.1 | -0.41 | - | -0.27 | -0.16 | -0.17 | - | -0.18 | -0.18 | -0.39 | - | -0.35 | -0.15 | -0.39 | - | - | 0.01 | -0.08 | - | - | - | - | - | - | -0.01 | - | - | - | -0.01 | - | - | -0.01 | -0.01 | -0.01 | - | -0.02 | - | -0.01 | - | -0.02 | - | - | - | -0.02 | -0.07 | -0.1 |
EBITDA per Share |
0.36 | 0.37 | - | 0.41 | 0.13 | -0.11 | - | 0.17 | -0.21 | -0.05 | - | 0.01 | -0.13 | -0.05 | - | -0.3 | -0.37 | -0.34 | - | -0.22 | -0.12 | -0.15 | - | -0.2 | -0.16 | -0.37 | - | -0.31 | -0.13 | -0.36 | - | - | 0.03 | 0.05 | - | - | - | - | - | - | -0.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.03 | -0.01 | - | - | -0.01 | -0.01 | - |
ROE % |
-502.80 | -503.35 | -509.88 | -517.13 | -31.02 | -29.43 | -19.81 | -22.21 | -19.43 | -13.81 | -9.71 | -13.00 | -8.65 | -15.25 | -12.41 | -18.54 | -18.73 | -24.01 | -12.94 | -33.63 | -46.84 | -73.30 | -69.96 | -82.61 | -67.24 | -50.36 | -20.43 | -29.91 | -11.95 | -5.58 | -3.12 | -50.48 | 36.10 | 82.53 | 81.47 | 38.57 | 303.97 | 205.54 | 153.80 | 167.86 | 261.61 | 59.06 | 80.40 | 169.54 | 256.74 | 278.11 | 262.62 | 330.98 | 243.15 | 180.06 | 107.84 | 144.57 | 76.99 | 68.13 | 29.95 | 38.71 | 172.99 | 288.27 | 295.82 | 8.75 | 171.02 | 116.05 |
ROA % |
-48.99 | -47.82 | -48.48 | -51.71 | -13.70 | -14.15 | -10.49 | -11.93 | -11.17 | -8.36 | -5.87 | -8.27 | -5.17 | -12.00 | -10.04 | -15.44 | -16.16 | -20.84 | -11.54 | -23.84 | -29.93 | -45.56 | -42.53 | -50.05 | -40.92 | -30.89 | -12.15 | -16.25 | -6.89 | -3.37 | -1.91 | -4.10 | 3.56 | 4.13 | 3.77 | 12.13 | -28.17 | -27.57 | -29.97 | -42.81 | -97.62 | -69.28 | -73.44 | -122.54 | -165.48 | -158.81 | -144.67 | -317.37 | -271.57 | -312.22 | -272.44 | -372.74 | -202.17 | -178.23 | -81.80 | -90.62 | -162.56 | -277.32 | -297.95 | -8.82 | -172.24 | -116.89 |
ROCE % |
13.05 | 7.69 | 2.93 | 3.98 | -6.16 | -8.75 | -6.25 | -7.71 | -12.61 | -10.41 | -7.78 | -13.96 | -20.27 | -26.09 | -23.63 | -29.12 | -25.86 | -21.11 | -11.44 | -32.23 | -43.91 | -68.21 | -65.19 | -74.35 | -57.28 | -41.91 | -14.69 | -18.95 | -4.50 | 10.58 | 12.39 | -15.67 | 104.37 | 155.90 | 144.54 | 172.36 | 84.09 | -13.82 | -70.64 | 125.38 | 607.53 | 866.56 | 848.68 | 898.13 | 714.11 | 210.25 | 67.55 | 67.55 | 67.55 | 67.55 | 67.55 | 67.55 | 67.55 | 67.55 | 67.55 | 92.20 | 67.94 | 71.55 | 65.44 | 24.65 | 25.18 | 15.61 |
Current Ratio |
1.1 | 1.1 | 1.8 | 1.1 | 1.6 | 1.6 | 1.8 | 1.8 | 2.3 | 2.5 | 2.5 | 2.4 | 4.3 | 3.2 | 3.2 | 3.6 | 4.2 | 6.3 | 5.8 | 8.4 | 9.4 | 11.0 | 2.5 | 2.5 | 2.5 | 2.5 | 2.4 | 2.4 | 2.4 | 2.4 | 1.5 | 1.8 | 1.5 | 1.5 | 1.1 | 1.1 | 1.1 | 1.1 | 0.8 | 0.8 | 0.8 | 0.8 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.6 | 0.3 | 0.1 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.5 | 0.5 | 0.5 | 0.5 |
DSO |
45.3 | 22.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.4 | 18.6 | 17.3 | - | 20.5 | 35.7 | 10.0 | - | 47.0 | 68.2 | 45.3 | - | 40.3 | 38.9 | 42.3 | - | 55.0 | 41.2 | 42.1 | - | 46.3 | 49.4 | 43.5 | - | 48.2 | 54.0 | 41.5 | - | 25.4 | 30.8 | 23.8 | - | 37.4 | 46.6 | 33.4 | - | 42.8 | 48.6 | 51.8 | - | 46.6 | 42.0 | 68.7 | - | 47.1 | 25.5 | - |
DIO |
166.5 | 139.3 | - | 167.9 | 157.1 | 147.0 | - | 150.6 | 177.0 | 216.0 | - | 246.0 | 163.8 | 149.8 | - | 123.8 | 213.5 | 239.1 | - | 272.4 | 231.1 | 223.8 | - | 233.9 | 300.5 | 261.8 | - | 238.9 | 203.4 | 191.1 | - | 183.2 | 268.8 | 254.6 | - | 282.2 | 395.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
55.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 33.3 | 79.2 | 77.5 | - | 56.0 | 50.5 | 53.0 | - | 55.3 | 71.0 | 84.1 | - | 108.0 | 92.0 | 77.9 | - | 139.9 | 90.5 | 82.7 | - | 89.4 | 125.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | 167.9 | 157.1 | 147.0 | - | 150.6 | 177.0 | 216.0 | - | 246.0 | 163.8 | 149.8 | - | 156.2 | 232.1 | 256.4 | - | 292.9 | 266.8 | 233.8 | - | 280.9 | 368.7 | 307.2 | - | 279.2 | 242.3 | 233.4 | - | 238.1 | 310.0 | 296.6 | - | 328.5 | 444.4 | 43.5 | - | 48.2 | 54.0 | 41.5 | - | 25.4 | 30.8 | 23.8 | - | 37.4 | 46.6 | 33.4 | - | 42.8 | 48.6 | 51.8 | - | 46.6 | 42.0 | 68.7 | - | 47.1 | 25.5 | - |
Cash Conversion Cycle |
- | - | - | 167.9 | 157.1 | 147.0 | - | 150.6 | 177.0 | 216.0 | - | 246.0 | 163.8 | 149.8 | - | 122.9 | 152.9 | 178.9 | - | 237.0 | 216.3 | 180.7 | - | 225.6 | 297.7 | 223.0 | - | 171.2 | 150.3 | 155.5 | - | 98.2 | 219.5 | 213.9 | - | 239.1 | 319.2 | 43.5 | - | 48.2 | 54.0 | 41.5 | - | 25.4 | 30.8 | 23.8 | - | 37.4 | 46.6 | 33.4 | - | 42.8 | 48.6 | 51.8 | - | 46.6 | 42.0 | 68.7 | - | 47.1 | 25.5 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Sanara MedTech , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Russia
Germany
Britain
China
